Predicting Survival in Pulmonary Arterial Hypertension
In pulmonary arterial hypertension, which endpoints and risk stratification tools offer the best means of predicting survival?
In pulmonary arterial hypertension, which endpoints and risk stratification tools offer the best means of predicting survival?
A study was conducted to evaluate the evolution and prognostic value of TAPSE/PASP ratio in cardiac resynchronization therapy recipients.
Among patients with pulmonary arterial hypertension, what is the relationship between Hispanic ethnicity, social determinants of health, and clinical outcomes?
How effective are the 3 most commonly used pulmonary arterial hypertension risk assessment tools — REVEAL, COMPERA, and FPHR — in predicting mortality risk?
Because oxidative stress and elevated ASK1 activity appear to play a role in vascular remodeling in PAH, ASK1 inhibition with selonsertib was studied.
Research presented at CHEST 2021 used machine learning to develop an algorithm for predicting poor response to initial PAH therapy, based on claims data.
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
A study investigated the efficacy of double or triple pharmacotherapy in pulmonary arterial hypertension.
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.